Company Overview

Provectus Biopharmaceuticals, Inc. is a development-stage biopharmaceutical company dedicated to investigating potential therapeutics for cancer and inflammatory dermatoses.

Recent Financial News

Date   Headline
Mar 17, 2020 PV-10® Abstract Previously Accepted for Presentation at Terminated American Association for Cancer Research (AACR) Annual Meeting 2020
Dec 12, 2019 Provectus Announces Presentation of Preliminary Results from Phase 1 Trial of PV-10® (rose bengal disodium) for Treatment of Metastatic Uveal Melanoma at ESMO I-O Congress 2019
Dec 02, 2019 Provectus Announces PV-10® Abstract Accepted for Presentation at Society of Interventional Radiology (SIR) 2020 Annual Scientific Meeting
Nov 21, 2019 Provectus Announces Presentation of Initial Results from Phase 1B Trial of PV-10® in Combination with KEYTRUDA® for Treatment of Checkpoint-Refractory Advanced Melanoma at SMR 2019 Congress
Nov 21, 2019 Provectus Announces Presentation of Updated Results from Phase 1B Trial of PV-10® in Combination with KEYTRUDA® for Treatment of Checkpoint-Naïve Advanced Melanoma at SMR 2019 Congress

Investor Contacts

Our Contact Form Mailing Address

Telephone: +1 (866) 594-5999
Fax: +1 (866) 998-0005
info@pvct.com

Provectus Biopharmaceuticals, Inc.
10025 Investment Drive, Suite 250
Knoxville, TN 37932
Investor Relations Media Relations

Provectus Biopharmaceuticals, Inc.
Email: investorrelations@pvct.com
Phone: +1 (866) 594-5999 x1

Provectus Biopharmaceuticals, Inc.
E-mail: mediarelations@pvct.com
Phone: +1 (866) 594-5999 x4
Transfer Agent

(i.e. stockholder records, transfer, change of address, etc.)
Broadridge Corporate Issuer Solutions, Inc.
P.O. Box 1342
Brentwood, NY 11717
E-mail: shareholder@broadridge.com
Telephone: +1 (877) 830-4936
Fax: +1 (215) 553-5402

Stock Performance

Today's Open 0.05
Volume 198,453
Day Range 0.04 - 0.06
52 Week Range 0.01 - 0.07
Bid/Ask 0.05 / 0.05
Bid/Ask Size 10,000 X 20,000
Previous Close 0.05
Market Cap 20.21 million
Shares Outstanding 388.58 million
Dividend/Yield 0.00 / 0.00%
EPS (TTM) -0.02
P/E Ratio (TTM) N/A

Recent XBRL Filings

Filing Date Form Type Description View
Mar 05, 2020 10-K Annual report htmlhtml   pdfpdf   xbrlxbrl  
Nov 12, 2019 10-Q Quarterly report htmlhtml   pdfpdf   xbrlxbrl  
Aug 08, 2019 10-Q Quarterly report htmlhtml   pdfpdf   xbrlxbrl  
May 13, 2019 10-Q Quarterly report htmlhtml   pdfpdf   xbrlxbrl  
May 09, 2019 10-K/A Annual report (Amendment) htmlhtml   pdfpdf